Why choose our Life Science and Healthcare lawyers?
Fieldfisher's life sciences group brings together highly-regarded specialists in intellectual property, regulatory, corporate, privacy and information as well as finance and competition. This multi-disciplinary offering means we can efficiently solve all of our clients' issues.
The team has a thorough understanding of the particular needs of pharmaceutical, biotech and medical devices clients and is able to call on specialist lawyers based in London, Paris, Brussels, Dusseldorf, Munich and Manchester.
We work with clients at all stages of innovation, from bench to bedside, and help companies to continually develop and grow their businesses within the strict regulatory requirements that can apply in the sector.
Our specialist regulatory and intellectual property lawyers work closely with our corporate lawyers who have experience of transactions totalling over $1bn in this sector alone. We are also proficient in negotiating agreements for the supply of materials, manufacturing of products and tooling, and global product distribution.
Through these various stages of growth, our lawyers help life sciences clients take advantage of their valuable intellectual property rights. This can be through research agreements, licences, collaborations or co-marketing arrangements. We also help to devise patent strategies based on defending a client’s own patents and/or challenging a competitor’s patents and/or developing strategies to avoid infringing third parties’ patents.
We advise on regulation of chemicals (REACH) and electrical equipment (WEEE and RoHS), and on avoiding the infringement of competition law, whether through agreements, concerted practices or mergers and acquisitions. Our life sciences lawyers work with our public regulatory lawyers, who are highly-experienced in judicial reviews and work with regulators across the life sciences sector.
We advise on
- The interpretation of and compliance with regulations
- Interactions with competent authorities, including challenging their decisions
- Data privacy issues around the handling of sensitive clinical trial data
- Investments, whether through funding rounds, flotations or mergers and acquisitions
